Evidence for combination therapy: According to the DELIGHT study [55], in individuals with T2D and CKD, the dapagliflozin (10 mg) and saxagliptin (2.5 mg) combination at the end of 24 weeks reduced the urine albumin creatinine ratio (−38.0% (−48.2 to −25.8), p < 0.0001) when compared to dapagliflozin monotherapy and HbA1c (−0.58% (−0.80 to −0.37), p < 0.0001) when compared to placebo. This evidence concerns the gene ALB and chronic kidney disease.